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Available online 2 February 2018The leucine-rich repeat kinase 2 (LRRK2) p.G2019S mutation is the most common genetic cause of Parkinson's dis-
ease (PD). An induced pluripotent stem cell (iPSC) line CSC-41was generated from a 75-year old patient diagnosed
with PD caused by a p.G2019S mutation in LRRK2. Skin ﬁbroblasts were reprogrammed using a non-integrating
Sendai virus-based technology to deliver OCT3/4, SOX2, c-MYC and KLF4 transcription factors. The generated iPSC
line exhibits expression of commonpluripotencymarkers, differentiates into the three germ layers andhas a normal
karyotype. The iPSC line can be used to explore the association between LRRK2mutation and PD.
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Fig. 1. Characterization of the iPSC line CSC 41C.
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The LRRK2mutation p.G2019S is the most common genetic cause of
Parkinson's disease (PD). The line CSC-41 was generated from a patient
with PD carrying a p.G2019S mutation in LRRK2 encoding for the leu-
cine-rich repeated kinase 2 (LRRK2) protein. This induced pluripotent
stem cell (iPSC) line can be used as a model to explore the link between
mutant LRRK2 and PD pathology.
Resource details
Mutations in LRRK2 result in autosomal-dominant familial PD and
have also been identiﬁed in sporadic PD cases with no family history
of the disease. LRRK2 is encoded by the LRRK2 gene, and is a protein
with GTPase and kinase activity. The most frequent LRRK2 mutation
among PD patients, is a glycine-to-serine substitution at amino acid
2019 (p.G2019S) which causes increased kinase activity and has been
reported to have implications in oxidative stress response and neuronal
plasticity (Reinhardt et al., 2013). Here we report the generation of an
induced pluripotent stem cell line (CSC-41) from a patient with PD car-
rying a p.G2019S LRRK2mutation. CSC-41 iPSC line can be used to better
understand the molecular mechanisms underlying p.G2019S LRRK2 as-
sociated PD.
To generate this line, skin ﬁbroblasts collected by punch skin bi-
opsy from a 75-year-old PD patient were reprogrammed using a
non-integrating Sendai virus-based technology. Brieﬂy, ﬁbroblasts
were seeded (75,000 cells/well) on a 12-well plate, two days before
transduction. The CytoTune™-iPS 2.0 Sendai Reprogramming Kit was
then used to deliver the four reprogramming factors (OCT3/4, SOX2,
c-MYC and KLF4). At day 7 post-transduction, the cells were re-seeded
onto irradiated mouse embryonic ﬁbroblasts (MEF)-feeder layer and
expanded until colonies presented an embryonic stem cell-like mor-
phology. At day 28, 12 colonieswere picked and expanded as individual
clones for 7 days. Three clones (CSC-41C, CSC-41I, CSC-41K) were fur-
ther selected, based on their morphology, for expansion and karyotype
analysis. All cloneswere characterized using themethodswepreviously
described (Holmqvist et al., 2016). Here, we present the characteriza-
tion of clone CSC-41C.
Brieﬂy, the generated clone, CSC-41C, expressed the common nuclear
and cell surface pluripotencymarkers, OCT4/NANOG and TRA1-81/SSEA4
(Fig. 1A), and exhibited alkaline phosphatase (ALP) activity (Fig. 1B). Ac-
cording to ﬂow cytometry analysis, N94% of the iPSCs were positive for
SSEA4 (Fig. 1C; non-stained iPSCs are shown in grey). Additional immu-
nocytochemistry analysis revealed elimination of the Sendai virus at
passage 11 (Fig. 1D). Fig. 1E depicts a normal female karyogram of the
CSC-41C clone. The identity of the generated iPSC line was conﬁrmed byTable 1
Characterization and validation.
Classiﬁcation Test Result
Morphology Photography Visual r
Phenotype Immunocytochemistry Positive
NANOG
Alkaline phosphatase activity Visible a
Flow cytometry 98.7% SS
Genotype Karyotype (G-banding) and resolution 46,XX, (
Identity STR analysis 10 sites
cell line
Mutation analysis (IF APPLICABLE) Sequencing Heteroz
p.G2019
Microbiology and virology Mycoplasma Mycopla
Differentiation potential Embryoid body formation Positive
beta-III-
spontan
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A
HLA tissue typing N/ADNA ﬁngerprint, showing genetic correspondence to parental ﬁbroblasts.
Themutation p.G2019Swas conﬁrmed by DNA sequencing (Fig. 1F). Em-
bryoid bodies (EBs) generated from CSC-41C iPSCs differentiate into the
three-germ layer, in vitro. Differentiated cells express endodermalmarker
alpha-fetoprotein (AFP), mesodermal marker smooth muscle actin
(SMA), and ectodermalmarker beta-III-tubulin (BIIITub) (Fig. 1G). During
the generation of the iPSC clones, plasmocin was used to prevent Myco-
plasma contamination.
Materials and methods
Fibroblast culture
Dermal ﬁbroblasts were collected by punch skin biopsy from a pa-
tient diagnosed with PD, after obtaining informed consent. The ﬁbro-
blasts were maintained in ﬁbroblast growth medium, composed of
DMEM media (ThermoFisher Scientiﬁc) with 10% fetal bovine serum
and 1% Penicillin-Streptomycin and passaged with 0.05% trypsin.
iPSC generation and expansion
For reprogramming, 75,000 cells were seeded on a 12-well plate and
maintained in ﬁbroblast growth medium. Two days after (day 0), the
cells were transduced using the three vector preparations (MOI = 5,
5, 3) included in the CytoTune™-iPS 2.0 Sendai Reprogramming Kit
(ThermoFisher Scientiﬁc). On the following day and on every other
day, the medium was replaced with fresh ﬁbroblast growth medium.
At day 7, the cells were re-seeded onto irradiated mouse embryonic ﬁ-
broblasts (MEF) feeder cells with ﬁbroblast growth medium. On the
day after and until colony picking, the cells were cultured inWiCell me-
dium composed of advanced DMEM/F12 (ThermoFisher Scientiﬁc), 20%
Knock-Out Serum Replacement (v/v, ThermoFisher Scientiﬁc), 2 mM L-
glutamine (Thermo Fisher Scientiﬁc), 1% non-essential amino acids
(NEAA, v/v,Millipore) and 0.1mMβ-mercaptoethanol (Sigma-Aldrich),
supplemented with 20 ng/ml FGF2 (ThermoFisher Scientiﬁc). On day
28, individual colonies were picked and re-seeded on a 24-well plate
containing fresh MEFs. One week after, three clones were selected and
further expanded on 6-well plates. The cells were passaged once a
week and seeded on the appropriate cell culture surface for characteri-
zation assays at the indicated passage numbers (Table 1).
Immunocytochemistry
The iPSC cultures were ﬁxed with 4% paraformaldehyde for 15 min
at room temperature (RT), permeabilized and blocked for 1 h at RT
with PBS containing 10% donkey serum and 0.1% TritonX-10 (Sigma)Data
ecord of the line: Normal Not shown but available with author
staining for pluripotency markers: OCT4,
, TRA1–81 and SSEA4
Fig. 1 panel A
ctivity Fig. 1 panel B
EA4 Fig. 1 panel C
300–400 bands resolution in average) Fig. 1 panel E
analyzed, all matched with parent ﬁbroblast Available with author
ygous Fig. 1 panel F
S mutation in LRRK2
sma testing by RT-PCR. Negative. Not shown but available with author
staining for smooth muscle actin,
tubulin and alpha-fetoprotein after
eous differentiation of embryoid bodies
Fig. 1 panel G
N/A
N/A
N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-OCT4 1:200 Millipore Cat# MAB4401, RRID:AB_2167852
PE-conjugated mouse anti-human Nanog 1:200 BD Biosciences Cat# 560483, RRID:AB_1645522
Mouse anti-TRA-1-81 1:200 Thermo Fisher Scientiﬁc Cat# 41-1100, RRID:AB_2533495
PE-conjugated mouse anti-SSEA4 1:200 Thermo Fisher Scientiﬁc Cat# A14766, RRID:AB_2534281
Sendai Chicken anti-Sendai virus 1:1000 Abcam Cat# ab33988, RRID:AB_777877
Differentiation markers Mouse anti-AFP 1:200 Sigma-Aldrich Cat# A8452, RRID:AB_258392
Mouse anti-SMA 1:200 Sigma-Aldrich Cat# A2547, RRID:AB_476701
Mouse anti-beta-III tubulin 1:200 Sigma-Aldrich Cat# T8660, RRID:AB_477590
Secondary antibodies Donkey anti-mouse Alexa Fluor® 488 1:400 Molecular Probes Cat# A-21202, RRID:AB_141607
Donkey anti-chicken Alexa Fluor® 488 1:400 Jackson ImmunoResearch Labs Cat# 703-545-155, RRID:AB_2340375
Donkey anti-mouse Alexa Fluor® 555 1:400 Thermo Fisher Scientiﬁc Cat# A-31570, RRID:AB_2536180
Primers
Target Forward/reverse primer (5′-3′)
Mutation sequencing LRRK2 TTTTGATGCTTGACATAGTGGAC/CACATCTGAGGTCAGTGGTTATC
47A. Marote et al. / Stem Cell Research 28 (2018) 44–47and incubated overnight at+4 °Cwith the primary antibodies (Table 2)
diluted in the blocking buffer. The secondary antibodies were thereafter
added for 1 h at RT in the dark, followed by nuclei counterstain with
DAPI (1:10,000 (Life Technologies)) and image acquisition on inverted
epiﬂuorescencemicroscope LRI - Olympus IX-73. Scale bars are 200 μm.
Alkaline phosphatase activity
Alkaline phosphatase staining was performed using Alkaline
Phosphatase Staining Kit (Stemgent, MA).
In vitro differentiation by embryoid body (EB) formation
Human iPSCs were grown for 2 weeks as embryoid bodies (EBs) in
low-attachment 24-well plates (Corning) in WiCell medium supple-
mented with 20 ng/ml FGF2. The EBs were then seeded on a 0.1% gela-
tin-coated 96-well plate (Greiner Bio-One) in DMEMmedia containing
10% fetal bovine serum and 1% Penicillin-Streptomycin for subsequent
spontaneous differentiation, with media changes every 2–3 days. After
2 weeks, the cells were ﬁxed and stained for three germ-layer markers
as described in the Table 2.
Karyotype analysis
The G-banding analysis was performed after 14 passages at 300–400
band resolution in average, at the Department of Clinical Genetics and
Pathology in Lund.
Mutation sequencing
Genomic DNA from ﬁbroblasts and iPSCs was extracted using con-
ventional lysis buffer composed of 100 mM Tris (pH 8.0), 200 mM
NaCl, 5 mM EDTA and 0.2% SDS in distilled autoclaved water supple-
mented with 1.5 mg/ml Proteinase K. The mutation, p.G2019S in
LRRK2, was conﬁrmed by direct DNA sequencing (Macrogen Europe,
Amsterdam, The Netherlands). Primers used for ampliﬁcation and di-
rected sequencing of LRRK2 around the mutation sites are listed in the
Table 2.
DNA ﬁngerprinting
Genomic DNA from ﬁbroblasts and iPSCs was isolated as described
above and ﬁngerprinting analyses were outsourced to the IdentiCellSTR proﬁling service (Department of Molecular Medicine, Aarhus Uni-
versity Hospital, Skejby, Denmark).
Mycoplasma detection
Absence of mycoplasma contamination was conﬁrmed by the real-
time PCRmethod at GATC Biotech AG (European Genome and Diagnos-
tics Centre, Konstanz, Germany).
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